162 related articles for article (PubMed ID: 28705838)
41. An animal model of allogeneic donor platelet refractoriness: the effect of the time of leukodepletion.
Blajchman MA; Bardossy L; Carmen RA; Goldman M; Heddle NM; Singal DP
Blood; 1992 Mar; 79(5):1371-5. PubMed ID: 1536960
[TBL] [Abstract][Full Text] [Related]
42. [Alloimmunization and transfusion refractoriness to thrombocyte substitution].
Söhngen D; Schneider W
Klin Wochenschr; 1991 Jul; 69(10):419-25. PubMed ID: 1942953
[TBL] [Abstract][Full Text] [Related]
43. A new platelet-specific antigen, Naka, involved in the refractoriness of HLA-matched platelet transfusion.
Ikeda H; Mitani T; Ohnuma M; Haga H; Ohtzuka S; Kato T; Nakase T; Sekiguchi S
Vox Sang; 1989; 57(3):213-7. PubMed ID: 2617957
[TBL] [Abstract][Full Text] [Related]
44. Transfused platelets enhance alloimmune responses to transfused KEL-expressing red blood cells in a murine model.
Madrid DJ; Santhanakrishnan M; Liu J; Gibb DR; Liu D; Natarajan P; Beitler D; Shi Z; Mo C; Tormey CA; Patel SR; Stowell SR; Hendrickson JE
Blood Transfus; 2019 Sep; 17(5):368-377. PubMed ID: 30418129
[TBL] [Abstract][Full Text] [Related]
45. Effect of six weekly transfusions on canine marrow grafts: tests for sensitization and abrogation of sensitization by procarbazine and antithymocyte serum.
Weiden PL; Storb R; Slichter S; Warren RP; Sale GE
J Immunol; 1976 Jul; 117(1):143-50. PubMed ID: 6593
[TBL] [Abstract][Full Text] [Related]
46. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components.
Eernisse JG; Brand A
Exp Hematol; 1981 Jan; 9(1):77-83. PubMed ID: 7238644
[TBL] [Abstract][Full Text] [Related]
47. Comparative study of alloimmune reactions induced by leukocyte and platelet transfusions in humans: characteristic changes of activation markers, gamma interferon, and FcR blocking antibody production.
Kotlán B; Gyódi E; Szabó T; Takács K; Troppmair J; Petri I; Padányi A; Kaiser G; Kassai M; Huber C
Hum Immunol; 1988 May; 22(1):19-29. PubMed ID: 3134315
[TBL] [Abstract][Full Text] [Related]
48. Related donor platelet transfusion improves platelet transfusion refractoriness in hematological patients.
Zhang JC; Ni LH; Tu Y; Hu HX
Front Med (Lausanne); 2023; 10():983644. PubMed ID: 36936203
[TBL] [Abstract][Full Text] [Related]
49. Use of 8-methoxypsoralen and ultraviolet-A pretreated platelet concentrates to prevent alloimmunization against class I major histocompatibility antigens.
Grana NH; Kao KJ
Blood; 1991 Jun; 77(11):2530-7. PubMed ID: 1828180
[TBL] [Abstract][Full Text] [Related]
50. A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions.
Sintnicolaas K; Löwenberg B
Br J Haematol; 1996 Mar; 92(4):1005-10. PubMed ID: 8616059
[TBL] [Abstract][Full Text] [Related]
51. The relationship between donor-recipient lymphocytotoxicity and the transfusion response using HLA-matched platelet concentrates.
Herzig RH; Terasaki PI; Trapani RJ; Herzig GP; Graw RG
Transfusion; 1977; 17(6):657-61. PubMed ID: 595123
[TBL] [Abstract][Full Text] [Related]
52. Transfusion-related immunomodulation: gamma irradiation alters the effects of leukoreduction on alloimmunization.
Nelson KA; Aldea GS; Warner P; Latchman Y; Gunasekera D; Tamir A; Gernsheimer T; Bolgiano D; Slichter SJ
Transfusion; 2019 Nov; 59(11):3396-3404. PubMed ID: 31608454
[TBL] [Abstract][Full Text] [Related]
53. A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy.
Blundell EL; Pamphilon DH; Fraser ID; Menitove JE; Greenwalt TJ; Snyder EL; Repucci AJ; Hedberg SL; Anderson JK; Buchholz DH; Kagen LR; Aster RH
Transfusion; 1996 Apr; 36(4):296-302. PubMed ID: 8623127
[TBL] [Abstract][Full Text] [Related]
54. Sensitization by platelet transfusion.
Brand A
Schweiz Med Wochenschr; 1991 Mar; 121(13):467-9. PubMed ID: 2031162
[TBL] [Abstract][Full Text] [Related]
55. Platelet transfusion therapy.
Slichter SJ
Hematol Oncol Clin North Am; 2007 Aug; 21(4):697-729, vii. PubMed ID: 17666286
[TBL] [Abstract][Full Text] [Related]
56. Immunomodulation by blood transfusions.
Roelen DL; van Rood JJ; Brand A; Claas FH
Vox Sang; 2000; 78 Suppl 2():273-5. PubMed ID: 10938968
[TBL] [Abstract][Full Text] [Related]
57. Approaches to preventing or reversing platelet alloimmunization using animal models.
Slichter SJ; Weiden PL; Kane PJ; Storb RF
Transfusion; 1988; 28(2):103-8. PubMed ID: 3354038
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of the tolerability and immunogenicity of ultraviolet C-irradiated autologous platelets in a dog model.
Pohler P; Lehmann J; Veneruso V; Tomm J; von Bergen M; Lambrecht B; Kohn B; Weingart C; Müller TH; Seltsam A
Transfusion; 2012 Nov; 52(11):2414-26. PubMed ID: 22404822
[TBL] [Abstract][Full Text] [Related]
59. Platelet transfusion. Current techniques, remaining problems, and future prospects.
Herman JH; Kamel HT
Am J Pediatr Hematol Oncol; 1987; 9(3):272-86. PubMed ID: 3314551
[TBL] [Abstract][Full Text] [Related]
60. A mini-review on platelet refractoriness.
Rebulla P
Haematologica; 2005 Feb; 90(2):247-53. PubMed ID: 15710579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
